Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

Abstract

This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.

Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer

“…Targeted therapies, particularly the anti-ERBB2 antibody trastuzumab (Herceptin) and its derivatives, alone or in combination, have greatly improved survival in ERBB2 + BC patients [ 41 , 42 , 43 ]. In contrast, there are limited targeted therapies available with modest therapeutic responses to target distant metastasis in ERBB2 + BC patients [ 3 , 44 , 45 ].…”

Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis

“…1) und eine deutliche Verlängerung des PFS und auch des OS erreichen [38][39][40][41], was zur Implementierung in nationale und internationale Leitlinien geführt hat [42]. Eine kürzlich veröffentlichte Arbeit des PRA-EGNANT-Netzwerks [43] zeigt die Einführung dieser Therapien in die "real-world" klinische Praxis [44]. Diese Arbeit konnte zeigen, dass über 80 % aller HER2-positiven Patientinnen bis zur 4.…”

Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis

“…1) und eine deutliche Verlängerung des PFS und auch des OS erreichen [38 -41], was zur Implementierung in nationale und internationale Leitlinien geführt hat [42]. Eine kürzlich veröffentlichte Arbeit des PRAEG-NANT-Netzwerks [43] zeigt die Einführung dieser Therapien in die "real-world" klinische Praxis [44]. Diese Arbeit konnte zeigen, dass über 80 % aller HER2-positiven Patientinnen bis zur 4.…”